Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01508221
Recruitment Status : Unknown
Verified July 2016 by Ronald Warnick, University of Cincinnati.
Recruitment status was:  Recruiting
First Posted : January 11, 2012
Last Update Posted : August 2, 2016
Information provided by (Responsible Party):
Ronald Warnick, University of Cincinnati

Brief Summary:
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.

Condition or disease Intervention/treatment Phase
Brain Metastasis Drug: Trental Dietary Supplement: Vitamin E Phase 2

Detailed Description:
The treatment phase of the study is 6 months. Study procedures will be conducted such as: history, physical and neurological exam, pregnancy testing (for women of child bearing age) and a Brain MRI. Follow-up appointments will be every 3 months for 1 year at which time, your participation in the study will be concluded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis
Study Start Date : June 2011
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : June 2017

Arm Intervention/treatment
Experimental: Trental + Vitamin E
Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
Drug: Trental
400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
Other Name: Pentoxifylline

Dietary Supplement: Vitamin E
400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months

Primary Outcome Measures :
  1. incidence of symptomatic radiation necrosis [ Time Frame: average 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor
  • Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation or by clinical confirmation by the treating physician based on MR imaging characteristics in the setting of a known history of cancer
  • Age > 18 years
  • Partial or total resection of a metastatic tumor are eligible

Exclusion Criteria:

  • Known sensitivity to vitamin E or Trental
  • Recent intracranial bleed or retinal hemorrhage
  • Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment
  • History of Avastin treatment
  • Anticipated need for treatment with Avastin
  • History of bleeding disorder
  • History of liver disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01508221

Layout table for location contacts
Contact: UC Cancer Institute 513-584-7698

Layout table for location information
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Contact: UC Cancer Institute    513-584-7698      
Principal Investigator: Ronald Warnick, MD         
Sponsors and Collaborators
University of Cincinnati
Layout table for investigator information
Principal Investigator: Ronald Warnick, MD University of Cincinnati

Layout table for additonal information
Responsible Party: Ronald Warnick, Medical Director, University of Cincinnati Brain Tumor Center, University of Cincinnati Identifier: NCT01508221    
Other Study ID Numbers: BTC-W1
First Posted: January 11, 2012    Key Record Dates
Last Update Posted: August 2, 2016
Last Verified: July 2016
Keywords provided by Ronald Warnick, University of Cincinnati:
brain metastasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Vitamin E
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Vasodilator Agents
Free Radical Scavengers